A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631

Status	RECRUITING
Phase	Phase 3
Sponsor	Merck Sharp & Dohme LLC
Enrollment	400 participants

Key Eligibility Criteria

Inclusion (5)

- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \& Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat

Exclusion (3)

- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving \<90% of assigned doses excluding suspensions or holds as assigned by the investigator

Locations (21 total)

University of Michigan (Site 6000), Ann Arbor, Michigan, United States
DUHS Duke Blood Cancer Center (Site 6005), Durham, North Carolina, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C (Site 6007), Columbus, Ohio, United States
... and 18 more locations